Fate Therapeutics Announces Oral Presentation On Natural Killer Cell Product Candidate FATE-NK100 At The 2016 ASH Annual Meeting

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that six abstracts highlighting the Company's programs, including an oral presentation on its natural killer (NK) cell product candidate FATE-NK100 as well as multiple poster presentations on its off-the-shelf cancer immunotherapy pipeline, have been accepted for presentation at the 58 th American Society of Hematology (ASH) Annual Meeting and Exposition. The meeting will be held December 3-6, 2016 in San Diego.

ASH Presentations on Fate Therapeutics' Programs

FATE-NK100: TITLE: Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function Frank Cichocki   Publication Number: 1225  Session Name: 711. Cell Collection and Processing: Immunotherapy, Immunomodulation, and Immune Reconstitution  Date and Time: Monday, December 5, 2016, 6:15 PM  Room: San Diego Convention Center, Room 30

Off-the-Shelf Cancer Immunotherapy: TITLE: Off-the-Shelf Natural Killer Cell Immunotherapy for Enhanced Antibody Directed Cellular CytotoxicityRyan Bjordahl Publication Number:  3363 Session Name: 703. Adoptive Immunotherapy: Poster II Date and Time: Sunday, December 4, 2016, 6:00 PM - 8:00 PM Location: San Diego Convention Center, Hall GH

TITLE: Genetically Enhanced Pluripotent Stem Cell-Derived T Lymphocytes for Off-the-Shelf Cellular Immunotherapy Raedun Clarke Publication Number: 2164 Session Name: 703. Adoptive Immunotherapy: Poster I Date and Time: Saturday, December 3, 2016, 5:30 PM - 7:30 PM Location: San Diego Convention Center, Hall GH

If you liked this article you might like

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Biotech Movers: Fate Shares Spike After Cancer Studies Progress

The Setup Is Good for a Bounce, but it Hasn't Happened Yet

3 Small Biotechs With Insider Buying

On the Hunt for Holiday Movers